An open, single-center, phase 1 study to evaluate safety of hypoxic preconditioned allogeneic bone marrow derived mesenchymal stem cell aiming to prevent acute kidney injury due to renal ischemia-reperfusion injury
- Conditions
- Neoplasms
- Registration Number
- KCT0003417
- Lead Sponsor
- Asan Medical Center
- Brief Summary
o clinically or statistically significant deterioration in renal function was observed except for an increase in serum creatinine at 30 days after injection. Acute kidney injury due to ischemia-reperfusion injury is considered risk factors such as diabetes, hypertension, and old age. Most of the subjects in this clinical trial did not have risk factors for acute kidney injury, and their renal function was normal before injection. It may not have happened. To determine the effectiveness of Cellgram-AKI injection, it is thought that a study targeting the high-risk group for acute renal injury is needed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 10
1) Patients =18 and <80 years of age who temporarily block the blood flow of the kidney and undergo partial renal resection for kidney tumors
2) A patient with a primary renal tumor with a diameter of 2 cm or less, clinical stage T1aN0M0 (without surrounding tissue or lymph node involvement or metastasis)
1) Patients with a history of blood diseases (malignant blood diseases: acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma)
2) Serum AST / ALT level >3 × upper limit of normal
3) Patients with a history of hypersensitivity against a gentamycin
4) Patients positive for pathogenic microorganisms (HIV, HBV, HCV, Syphilis)
5) Patients unable to compliance with protocol and follow-up
6) Patients with a history of substance abuse in the past year
7) Those who participated in other clinical trials in the past 30 days before registration.
8) Patients to be inappropriate to participate in the study according to the investigator
9) Uncontrolled hypertension or hypotension (systolic blood pressure >170 or <90 mmHg, diastolic pressure >100 or <50 mmHg)
10) Those who being treated for severe infectious disease
11) Pregnant women, lactating women and those who disagree with contraception
12) Those who suffered or sufferring another malignant tumors excluding primary kidney tumors
13) Patients with a single kidney
14) patients with chronic kidney disease V (glomerular filtration rate <15 ml / min per 1.73 m² or during dialysis)
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse event;Laboratory test;Vital sign;Physical examination
- Secondary Outcome Measures
Name Time Method Serum creatinine;Computed tomography and DTPA (Diethylene Tetramine Penta-Acetic acid) scan